MST1R

Summary

MST1R (macrophage stimulating 1 receptor, HGNC:7381) is a protein-coding gene on chromosome 3p21.31, encoding Macrophage-stimulating protein receptor (Q04912). Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand.

This gene encodes a cell surface receptor for macrophage-stimulating protein (MSP) with tyrosine kinase activity. The mature form of this protein is a heterodimer of disulfide-linked alpha and beta subunits, generated by proteolytic cleavage of a single-chain precursor. The beta subunit undergoes tyrosine phosphorylation upon stimulation by MSP. This protein is expressed on the ciliated epithelia of the mucociliary transport apparatus of the lung, and together with MSP, thought to be involved in host defense. Alternative splicing generates multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing.

Source: NCBI Gene 4486 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nasopharyngeal carcinoma, susceptibility to, 3 (Limited, GenCC)
• GWAS associations: 19
• Clinical variants (ClinVar): 273 total — 1 likely-pathogenic
• GTEx eGene: eQTL in 34 tissues, sQTL in 7 (q < 0.05)
• Phenotypes (HPO): 2
• Drug target: yes — 4 curated mechanism-of-action drugs; 42 molecules with ChEMBL bioactivity (top 1% of genes corpus-wide)
• Approved drugs (ChEMBL mechanism of action): 1 — Crizotinib
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.98 (unconstrained)
• MANE Select transcript: NM_002447
• Notable: 273 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7381
Approved symbol	MST1R
Name	macrophage stimulating 1 receptor
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	CDw136, CD136
Ensembl gene	ENSG00000164078
Ensembl biotype	protein_coding
OMIM	600168
Entrez	4486

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 24 protein_coding, 7 nonsense_mediated_decay, 7 retained_intron

MANE Select: ENST00000296474

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 6, TSL 2: 1, TSL 3: 2, TSL 4: 1, TSL 5: 3

ENST00000296474, ENST00000344206, ENST00000411578, ENST00000434765, ENST00000440292, ENST00000463789, ENST00000467110, ENST00000468525, ENST00000485044, ENST00000490053, ENST00000493535, ENST00000497001, ENST00000621387, ENST00000714251, ENST00000714252, ENST00000858906, ENST00000858907, ENST00000858908, ENST00000858909, ENST00000858910, ENST00000858911, ENST00000858912, ENST00000858913, ENST00000858914, ENST00000858915, ENST00000858916, ENST00000858917, ENST00000858918, ENST00000858919, ENST00000858920, ENST00000858921, ENST00000858922, ENST00000944850, ENST00001053126, ENST00001053127, ENST00001053128, ENST00001053129, ENST00001145193

RefSeq mRNA: 4 — MANE Select: NM_002447 NM_001244937, NM_001318913, NM_001437543, NM_002447

CCDS: CCDS2807, CCDS58833, CCDS82777

Canonical transcript exons

ENST00000296474 — 20 exons

Exon	Start	End
ENSE00003292427	49895961	49896107
ENSE00003549554	49898867	49898995
ENSE00003566005	49898051	49898211
ENSE00003583713	49897520	49897685
ENSE00003603086	49899075	49899263
ENSE00003681115	49898518	49898688
ENSE00004023332	49895167	49895373
ENSE00004023333	49891197	49891306
ENSE00004023334	49890485	49890650
ENSE00004023335	49896729	49896890
ENSE00004023336	49891399	49891580
ENSE00004023337	49896540	49896633
ENSE00004023338	49897280	49897416
ENSE00004023341	49896195	49896404
ENSE00004023342	49895715	49895880
ENSE00004023343	49887002	49887562
ENSE00004023344	49902380	49903873
ENSE00004023345	49889924	49890060
ENSE00004023348	49891758	49891838
ENSE00004023349	49895447	49895548

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 97.15.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3794 / max 95.6933, expressed in 399 samples.

Highest expression (Bgee): mucosa of transverse colon, skin of leg, lower esophagus mucosa, skin of abdomen, rectum.

Genetic regulation across tissues (GTEx eQTL / sQTL)

MST1R is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 34 tissues and its splicing (sQTL) in 7 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 41 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Skin Not Sun Exposed Suprapubic	sqtl	2.0e-26	+1.06	3:49890070:G:T
Skin Sun Exposed Lower leg	sqtl	2.2e-20	+0.89	3:49890289:A:C
Skin Not Sun Exposed Suprapubic	eqtl	1.8e-18	+0.21	3:49912401:A:T
Brain Cerebellum	eqtl	2.4e-17	-0.52	3:50026991:G:A
Skin Sun Exposed Lower leg	eqtl	1.1e-14	+0.17	3:49887507:T:C
Adipose Subcutaneous	eqtl	4.8e-14	+0.31	3:49904003:G:A
Cells Cultured fibroblasts	eqtl	8.3e-13	+0.37	3:49844916:C:T
Brain Cerebellar Hemisphere	eqtl	8.5e-13	+0.43	3:49872651:T:C
Thyroid	eqtl	4.1e-12	+0.26	3:49904003:G:A
Nerve Tibial	eqtl	8.2e-11	+0.29	3:49912401:A:T
Muscle Skeletal	eqtl	1.4e-10	+0.26	3:49904003:G:A
Lung	eqtl	8.9e-10	+0.19	3:49873722:G:A
Artery Tibial	eqtl	3.2e-09	-0.32	3:50050833:T:C
Esophagus Mucosa	sqtl	3.4e-08	+0.70	3:49923318:C:T
Brain Nucleus accumbens basal ganglia	eqtl	5.9e-08	-0.39	3:50003880:C:T
Brain Caudate basal ganglia	eqtl	1.9e-07	+0.39	3:49934081:C:A
Esophagus Muscularis	eqtl	3.5e-07	+0.17	3:49892782:C:T
Testis	sqtl	3.7e-07	+0.92	3:49891592:C:A
Brain Cortex	eqtl	6.5e-07	+0.41	3:49860567:A:G
Artery Aorta	eqtl	8.6e-07	+0.30	3:49904003:G:A

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
42284	1.3794	399

Top tissues by expression

showing 100 of 286 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	97.15	gold quality
skin of leg	UBERON:0001511	94.27	gold quality
lower esophagus mucosa	UBERON:0035834	94.06	gold quality
skin of abdomen	UBERON:0001416	93.86	gold quality
rectum	UBERON:0001052	92.60	gold quality
body of stomach	UBERON:0001161	92.04	gold quality
transverse colon	UBERON:0001157	91.72	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.05	gold quality
zone of skin	UBERON:0000014	90.20	gold quality
ileal mucosa	UBERON:0000331	90.16	gold quality
gall bladder	UBERON:0002110	90.06	gold quality
esophagus mucosa	UBERON:0002469	89.40	gold quality
small intestine	UBERON:0002108	89.07	gold quality
stomach	UBERON:0000945	88.88	gold quality
mucosa of stomach	UBERON:0001199	87.84	gold quality
upper lobe of left lung	UBERON:0008952	87.10	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.02	gold quality
duodenum	UBERON:0002114	85.71	gold quality
upper lobe of lung	UBERON:0008948	85.35	gold quality
pancreatic ductal cell	CL:0002079	85.05	silver quality
intestine	UBERON:0000160	84.66	gold quality
colon	UBERON:0001155	83.86	gold quality
large intestine	UBERON:0000059	83.69	gold quality
fundus of stomach	UBERON:0001160	83.56	gold quality
right lung	UBERON:0002167	83.47	gold quality
colonic mucosa	UBERON:0000317	82.96	gold quality
apex of heart	UBERON:0002098	82.96	gold quality
esophagus	UBERON:0001043	82.57	gold quality
jejunal mucosa	UBERON:0000399	82.10	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	81.95	gold quality
vagina	UBERON:0000996	81.74	gold quality
right testis	UBERON:0004534	81.61	gold quality
left testis	UBERON:0004533	81.44	gold quality
mucosa of sigmoid colon	UBERON:0004993	81.44	gold quality
minor salivary gland	UBERON:0001830	81.19	gold quality
pylorus	UBERON:0001166	79.68	gold quality
body of pancreas	UBERON:0001150	79.52	gold quality
mouth mucosa	UBERON:0003729	79.08	gold quality
vermiform appendix	UBERON:0001154	78.65	gold quality
testis	UBERON:0000473	77.62	gold quality
sigmoid colon	UBERON:0001159	77.61	gold quality
metanephros cortex	UBERON:0010533	77.27	gold quality
right lobe of thyroid gland	UBERON:0001119	76.89	gold quality
upper arm skin	UBERON:0004263	76.82	gold quality
saliva-secreting gland	UBERON:0001044	76.73	gold quality
muscle layer of sigmoid colon	UBERON:0035805	76.70	gold quality
omental fat pad	UBERON:0010414	76.69	gold quality
colonic epithelium	UBERON:0000397	76.63	gold quality
peritoneum	UBERON:0002358	76.59	gold quality
upper leg skin	UBERON:0004262	76.36	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	75.90	gold quality
caecum	UBERON:0001153	75.32	gold quality
left lobe of thyroid gland	UBERON:0001120	75.31	gold quality
lower esophagus	UBERON:0013473	75.30	gold quality
lower esophagus muscularis layer	UBERON:0035833	75.24	gold quality
pancreas	UBERON:0001264	75.07	gold quality
ectocervix	UBERON:0012249	74.73	gold quality
adipose tissue of abdominal region	UBERON:0007808	74.72	gold quality
nasal cavity epithelium	UBERON:0005384	74.45	silver quality
thyroid gland	UBERON:0002046	74.07	gold quality
palpebral conjunctiva	UBERON:0001812	73.96	gold quality
lung	UBERON:0002048	73.88	gold quality
adenohypophysis	UBERON:0002196	73.86	gold quality
endocervix	UBERON:0000458	73.51	gold quality
urinary bladder	UBERON:0001255	73.12	gold quality
ascending aorta	UBERON:0001496	72.23	gold quality
thoracic aorta	UBERON:0001515	72.00	gold quality
right uterine tube	UBERON:0001302	71.81	gold quality
islet of Langerhans	UBERON:0000006	71.63	gold quality
cortical plate	UBERON:0005343	71.03	gold quality
mucosa of urinary bladder	UBERON:0001259	70.86	silver quality
nasal cavity mucosa	UBERON:0001826	70.83	gold quality
pituitary gland	UBERON:0000007	70.36	gold quality
heart left ventricle	UBERON:0002084	70.36	gold quality
tongue squamous epithelium	UBERON:0006919	70.03	gold quality
descending thoracic aorta	UBERON:0002345	69.61	gold quality
cardiac ventricle	UBERON:0002082	69.46	gold quality
tonsil	UBERON:0002372	69.18	gold quality
right hemisphere of cerebellum	UBERON:0014890	69.17	gold quality
uterine cervix	UBERON:0000002	69.13	gold quality
gingival epithelium	UBERON:0001949	69.09	silver quality
cervix squamous epithelium	UBERON:0006922	68.97	gold quality
skin of hip	UBERON:0001554	68.77	gold quality
cerebellar hemisphere	UBERON:0002245	68.54	gold quality
left uterine tube	UBERON:0001303	68.49	gold quality
smooth muscle tissue	UBERON:0001135	68.31	gold quality
cerebellar cortex	UBERON:0002129	68.31	gold quality
jejunum	UBERON:0002115	68.29	gold quality
cardia of stomach	UBERON:0001162	68.18	gold quality
right atrium auricular region	UBERON:0006631	68.07	gold quality
prostate gland	UBERON:0002367	68.02	gold quality
anatomical system	UBERON:0000467	67.54	gold quality
endometrium epithelium	UBERON:0004811	67.41	gold quality
right ovary	UBERON:0002118	67.37	gold quality
body of uterus	UBERON:0009853	67.36	gold quality
squamous epithelium	UBERON:0006914	67.05	silver quality
multicellular organism	UBERON:0000468	67.03	gold quality
material anatomical entity	UBERON:0000465	67.01	gold quality
epithelium of bronchus	UBERON:0002031	67.01	gold quality
aorta	UBERON:0000947	66.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.00
E-CURD-53	no	158.90

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 69 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Skin 1	tissue	30.2	medium
Stomach 1	tissue	25.5	medium
Duodenum	tissue	18.2	medium
Small intestine	tissue	16.1	medium
Colon	tissue	12.1	medium
Rectum	tissue	10.3	medium
Gallbladder	tissue	6.4	high
Vagina	tissue	5.6	low
Urinary bladder	tissue	5.3	medium
Lung	tissue	5.2	high
Thymus	tissue	4.8
Esophagus	tissue	3.6	medium
Appendix	tissue	3.6	medium
Tonsil	tissue	3.2	medium
Breast	tissue	1.8	medium
Testis	tissue	1.8	medium
Lymph node	tissue	1.6	medium
Salivary gland	tissue	1.6	medium
Cervix	tissue	1.5	medium
Pancreas	tissue	1.4	medium
Pituitary gland	tissue	1.1
Smooth muscle	tissue	1.0	medium
Thyroid gland	tissue	0.9	high
Adipose tissue	tissue	0.8	medium
Skeletal muscle	tissue	0.8	medium
Choroid plexus	tissue	0.8
Hippocampus	tissue	0.8	medium
Fallopian tube	tissue	0.8	medium
Heart muscle	tissue	0.7	medium
Endometrium 1	tissue	0.6	medium
Nucleus accumbens	tissue	0.6
Prostate	tissue	0.6	medium
Seminal vesicle	tissue	0.5	medium
Epididymis	tissue	0.5	medium
Placenta	tissue	0.5	high
Spleen	tissue	0.5	low
Postcentral gyrus	tissue	0.5
Ovary	tissue	0.4	high
Locus coeruleus	tissue	0.4
Tongue	tissue	0.3
Kidney	tissue	0.3	medium
Frontal cortex	tissue	0.2
Superior colliculi	tissue	0.2
Spinal cord	tissue	0.2
Prefrontal cortex	tissue	0.1
Cerebral cortex	tissue	0.1	medium
Retina	tissue	0.1
Parathyroid gland	tissue	0.1	medium
Motor cortex	tissue	0.1
Midbrain	tissue	0.1
Thalamus	tissue	0.1
Substantia nigra	tissue	0.1
Liver	tissue	0.1	medium
Bone marrow	tissue	0.1	low
Hippocampal formation	tissue	0.1
Entorhinal cortex	tissue	0.1
Retrosplenial and cingulate cortex	tissue	0.1
Somatosensory cortex	tissue	0.1
Retrosplenial cortex	tissue	0.1
Temporal cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Blood vessel (1.0), Cerebellar cortex (0.9), Claustrum (0.9), Inferior frontal gyrus, opercular (0.9), Orbitofrontal gyrus, anterior (0.9).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EGR1, HIF1A, IRF6, NFE2L2, NFKB, NFKBIA, RELA, SMAD4, SP1, TXK

miRNA regulators (miRDB)

Targeting MST1R by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

18 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-633	98.35	69.45	1167
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-2682-3P	97.10	66.16	840
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-3126-5P	96.87	65.83	912
HSA-MIR-6875-5P	96.87	65.49	958

Functional genomics

gnomAD constraint: pLI 4.11e-28, LOEUF 0.985, missense Z 1.75 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000296474 — one region, missense o/e 0.91.

Literature-anchored findings (GeneRIF, showing 40)

• overexpression of human wild-type RON causes the formation of lung tumors with unique biological characteristics in vivo (PMID:12214279)
• Transgenic mice in which surfactant protein C promoter was used to express human wild-type RON in distal lung epithelial cells developed multiple RON-expressing lung adenomas with distinct morphology & growth pattern which progressed to adenocarcinoma. (PMID:12419829)
• These data suggest that RON expression is altered in certain primary colon cancers. Abnormal accumulation of RON variants may play a role in the progression of certain colorectal cancers in vivo (PMID:12527888)
• HYAL2 receptor protein is associated with the RON receptor tyrosine kinase, rendering it functionally silent. (PMID:12676986)
• immunostaining and Western blot showed Ron in normal kidney and in all oncocytomas but never in renal cell carcinomas or in the renal carcinoma cell line Caki-1; Ron was expressed in phosphorylated, i.e., active, form (PMID:12766581)
• Ron tyrosine kinase receptor desensitization mediated by c-Cbl and its binding partner Grb2. (PMID:12802274)
• These data suggest that coexpression of the MET and RON receptors confer a selective advantage to ovarian cancer cells and might promote ovarian cancer progression. (PMID:12915129)
• Data show that macrophage stimulating protein (MSP) and its receptor (Ron) induce phosphorylation of both Ron and alpha6beta4 integrin, and result in activation of alpha3beta1 integrin. (PMID:12919677)
• the ron-sema domain can suppress the growth of macrophage-stimulating protein-responsive cells in culture (PMID:14597639)
• persistent RON expression and activation cause the loss of epithelial phenotypes (PMID:15001985)
• RON receptor can interact with each of the three members of the class B Plexins and control tumor invasive growth. (PMID:15184888)
• altered expression of RON in colon cancer cells is required to maintain tumorigenic phenotypes (PMID:15378025)
• Data suggest that RON initiates signaling pathways that negatively regulate HIV-1 transcription in monocytes/macrophages, and that HIV-1 suppresses RON function by decreasing protein levels in the brain to assure efficient replication. (PMID:15557181)
• Receptor RON and uts ligand macrophage stimulating protein are involved in the pathophysiology of endometriosis. (PMID:15764806)
• co-expression of RON and MET is associated with aggressive phenotype in node-negative breast cancer patients (PMID:15788670)
• The proto-oncogene, c-Cbl, which modulates ubiquitylation of RON, was increased in glia in both multiple sclerosis brains and experimental autoimmune encephalomyelitis spinal cords (PMID:15929040)
• altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity (PMID:16166096)
• Mst1r tyrosine kinase-domain deficient-mice have decreased survival times, alterations in cytokine and nitric oxide regulation, and an earlier onset of pulmonary pathology compared with control mice during acute lung injury (PMID:16166746)
• RON activation induced molecular and cellular alterations consistent with epithelial-mesenchymal (EMT) transition. (PMID:17311308)
• These data suggest that high molecular form hyaluronan is broken down by reactive oxygen species to form low-molecular-weight fragments that signal via RHAMM and RON to stimulate beat frequency. (PMID:17395888)
• overexpression of MSP, MT-SP1, and MST1R was a strong independent indicator of both metastasis and death in human breast cancer (PMID:17456594)
• This study reveals for the first time that RON alone is sufficient to induce complete and stabilized EMT in MDCK cells. (PMID:17588532)
• RONdelta170 is a naturally occurring variant with dominant negative activities and has potential for inhibiting RON-mediated tumorigenic activities in colorectal cancer cells. (PMID:17611409)
• RON receptor signaling may contribute to pancreatic carcinogenesis (PMID:17616662)
• high expression of Ron in the colorectal mucosa of ulcerative colitis patients suggests that this receptor might play roles in the pathophysiological background of this disease (PMID:18019691)
• Translocation of c-Met to the nucleus depends upon the adaptor protein Gab1 and importin beta1, and formation of Ca(2+) signals in turn depends upon this translocation (PMID:18073207)
• a clear link between Sp1-dependent RON tyrosine kinase expression and invasion of breast carcinoma cells. (PMID:18165235)
• the linkage disequilibrium with these functional MST1R variants implicate this gene as having a possible role in Crohn Disease pathogenesis. (PMID:18200509)
• RON activation differentially regulates claudin expression in epithelial cells (PMID:18204077)
• RON represses HIV transcription at multiple transcriptional check points including initiation, elongation and chromatin organization. (PMID:18209063)
• We found that RON was over expressed in bladder cancer but RON over expression was not associated with overall survival or other clinical parameters (PMID:18221954)
• loss of Smad4 contributes to aberrant RON expression and cross-talk of Smad4-independent TGF-beta signaling and the RON pathway promotes an invasive phenotype (PMID:18310076)
• The regulation of human RON gene expression by nuclear factor-kappaB; a potential therapeutic role for curcumin in blocking RON tyrosine kinase-mediated invasion of carcinoma cells. (PMID:18593918)
• study demonstrates that HIV-1 Tat targets the receptor tyrosine kinase recepteur d’origine nantais (RON), which negatively regulates inflammation & HIV transcription, for proteosome degradation (PMID:18606710)
• Ron is a critical factor in tumorigenesis. (PMID:18620091)
• RON has 2 alternative SRC-kinase-mediated modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells: an MSP-dependent increase in cell proliferation & migration and MSP-independent increased cell survival. (PMID:18836480)
• The entire C-terminus is required for RON or RON160-mediated intracellular signaling events leading to various cellular activities. (PMID:18950514)
• RON expression is significant in gastric carcinoma tissue and corresponding paraneoplastic tissue, but is not expressed in normal gastric mucosa. RON expression in gastric carcinoma tissue was not related to patient survival rates. (PMID:19040718)
• Results demonstrate that Ron plays an essential role in maintaining malignant phenotypes of colon cancer cells through regulating mutant PI3K activity. (PMID:19224914)
• RON is involved in mesangial cell proliferation under both physiological and pathological conditions (PMID:19242504)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mst1ra	ENSDARG00000060235
mus_musculus	Mst1r	ENSMUSG00000032584
rattus_norvegicus	Mst1r	ENSRNOG00000032618

Paralogs (53): INSRR (ENSG00000027644), MUSK (ENSG00000030304), FLT4 (ENSG00000037280), EPHA3 (ENSG00000044524), ROS1 (ENSG00000047936), LTK (ENSG00000062524), ERBB3 (ENSG00000065361), TIE1 (ENSG00000066056), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078), EPHA8 (ENSG00000070886), FGFR1 (ENSG00000077782), EPHA6 (ENSG00000080224), TYRO3 (ENSG00000092445), FLT1 (ENSG00000102755), MET (ENSG00000105976), EPHB6 (ENSG00000106123), PDGFRB (ENSG00000113721), EPHA4 (ENSG00000116106), TEK (ENSG00000120156), FLT3 (ENSG00000122025), KDR (ENSG00000128052), EPHB2 (ENSG00000133216), PDGFRA (ENSG00000134853), EPHA7 (ENSG00000135333), IGF1R (ENSG00000140443), NTRK3 (ENSG00000140538), ERBB2 (ENSG00000141736), EPHA2 (ENSG00000142627), EPHA5 (ENSG00000145242), EGFR (ENSG00000146648), EPHA1 (ENSG00000146904), NTRK2 (ENSG00000148053), MERTK (ENSG00000153208), EPHB1 (ENSG00000154928), KIT (ENSG00000157404), FGFR4 (ENSG00000160867), DDR2 (ENSG00000162733), RYK (ENSG00000163785), LMTK2 (ENSG00000164715), RET (ENSG00000165731), AXL (ENSG00000167601), ROR2 (ENSG00000169071), ALK (ENSG00000171094), INSR (ENSG00000171105), ERBB4 (ENSG00000178568), CSF1R (ENSG00000182578), EPHB3 (ENSG00000182580), EPHA10 (ENSG00000183317), ROR1 (ENSG00000185483), EPHB4 (ENSG00000196411), NTRK1 (ENSG00000198400), DDR1 (ENSG00000204580)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:99614) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 20 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal macrophage physiology	3
increased susceptibility to Retroviridae infection	3
enlarged spleen	2
increased susceptibility to bacterial infection	2
abnormal type IV hypersensitivity reaction	2
abnormal ovary morphology	1
small ovary	1
hepatic necrosis	1
increased inflammatory response	1
decreased susceptibility to bacterial infection	1
increased circulating alanine transaminase level	1
decreased spleen weight	1
increased acute inflammation	1
increased interferon-gamma secretion	1
increased circulating interferon-gamma level	1
increased susceptibility to endotoxin shock	1
increased susceptibility to xenobiotic induced morbidity/mortality	1
embryonic lethality between implantation and somite formation, complete penetrance	1
decreased susceptibility to Retroviridae infection	1
decreased superovulation rate	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Felis catus	A0M8S8	100.0%	Diamond
Neofelis nebulosa	Q07E37	100.0%	Diamond
Pan troglodytes	Q2QLF1	99.8%	Diamond
Gorilla gorilla gorilla	Q2IBF2	99.7%	Diamond
Pongo abelii	Q2IBD8	99.5%	Diamond
Papio anubis	A0M8R7	99.3%	Diamond
Colobus guereza	Q07DZ1	99.3%	Diamond
Chlorocebus aethiops	Q2IBA6	99.3%	Diamond
Aotus nancymaae	Q07DV8	99.1%	Diamond
Nomascus leucogenys	Q07DY1	99.1%	Diamond
Ateles geoffroyi	Q09YL1	99.1%	Diamond
Drosophila sechellia	B4HNW4	99.0%	Diamond
Drosophila simulans	B4QC63	99.0%	Diamond
Saimiri boliviensis boliviensis	Q09YH7	99.0%	Diamond
Drosophila persimilis	B4GBH0	98.9%	Diamond
Drosophila pseudoobscura pseudoobscura	Q290N5	98.9%	Diamond
Plecturocebus moloch	Q2QLC0	98.6%	Diamond
Drosophila melanogaster	Q6AWJ9	98.5%	Diamond
Callithrix jacchus	Q2QLG5	97.7%	Diamond
Ovis aries	Q09YI9	97.5%	Diamond
Bos taurus	Q769I5	97.5%	Diamond
Drosophila erecta	B3NS99	97.4%	Diamond
Drosophila yakuba	B4P5Q9	97.4%	Diamond
Muntiacus muntjak	Q09YK0	97.4%	Diamond
Eulemur macaco macaco	Q2IBG7	97.4%	Diamond
Microcebus murinus	Q2QL89	97.4%	Diamond
Mustela putorius furo	Q07E24	96.4%	Diamond
Canis lupus familiaris	Q75ZY9	96.4%	Diamond
Xenopus tropicalis	A0JM20	95.5%	Diamond
Xenopus laevis	Q8QFP9	95.5%	Diamond
Equus caballus	Q2QLA9	94.9%	Diamond
Sus scrofa	Q2QLE0	94.9%	Diamond
Otolemur garnettii	Q2QLH6	94.0%	Diamond
Atelerix albiventris	Q00PJ8	92.0%	Diamond
Loxodonta africana	Q108U6	91.8%	Diamond
Dasypus novemcinctus	Q07E48	91.4%	Diamond
Oryctolagus cuniculus	Q09YN5	91.2%	Diamond
Rhinolophus ferrumequinum	Q2IBC0	90.1%	Diamond
Drosophila ananassae	B3MH43	88.7%	Diamond
Echinops telfairi	A1X150	87.8%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
SEMA3F-AS1	ncRNA	100129060
RBM5-AS1	ncRNA	100775107
RBM5	protein-coding	10181
SEMA3F	protein-coding	6405
MON1A	protein-coding	84315
MIR5193	ncRNA	100847079
TRAIP	protein-coding	10293
UBA7	protein-coding	7318
CAMKV	protein-coding	79012
RBM6	protein-coding	10180

Protein

Protein identifiers

Macrophage-stimulating protein receptor — Q04912 (reviewed: Q04912)

Alternative names: CDw136, Protein-tyrosine kinase 8, p185-Ron

All UniProt accessions (6): Q04912, A0AAQ5BHR6, A0AAQ5BHX4, H7C074, H7C3Z8, J3KQS7

UniProt curated annotations — full annotation on UniProt →

Function. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Also plays a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

Subunit / interactions. Heterodimer of an alpha chain and a beta chain which are disulfide linked. Binds PLXNB1. Associates with and is negatively regulated by HYAL2. Interacts when phosphorylated with downstream effectors including PIK3R1, PCLG1, GRB2 and GAB1. Interacts with integrin beta1/ITGB1 in a ligand-independent fashion.

Subcellular location. Membrane.

Tissue specificity. Expressed in colon, skin, lung and bone marrow.

Post-translational modifications. Proteolytic processing yields the two subunits. Autophosphorylated in response to ligand binding on Tyr-1238 and Tyr-1239 in the kinase domain leading to further phosphorylation of Tyr-1353 and Tyr-1360 in the C-terminal multifunctional docking site. Ubiquitinated. Ubiquitination by CBL regulates the receptor stability and activity through proteasomal degradation. O-mannosylation of IPT/TIG domains on Thr or Ser residues by TMEM260 is required for protein maturation. O-mannosylated residues are composed of single mannose glycans that are not elongated or modified.

Disease relevance. Nasopharyngeal carcinoma, 3 (NPCA3) [MIM:617075] A form of nasopharyngeal carcinoma, a malignant neoplasm that originates in the nasopharyngeal epithelium and includes 4 subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and papillary adenocarcinoma. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Activity regulation. In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.

Miscellaneous. Lacks part of the extracellular domain, oligomerizes and is constitutively activated. Expressed at higher level in cancer cells.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q04912-1	RON	yes
Q04912-2	Delta-RON, sf-RON
Q04912-3	RON-1
Q04912-4	RON-2
Q04912-5	RON-3
Q04912-6	RON-4
Q04912-7	RON-5

RefSeq proteins (4): NP_001231866, NP_001305842, NP_001424472, NP_002438* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR001627	Semap_dom	Domain
IPR002165	Plexin_repeat	Repeat
IPR002909	IPT_dom	Domain
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR014756	Ig_E-set	Homologous_superfamily
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR016201	PSI	Domain
IPR016244	Tyr_kinase_HGF/MSP_rcpt	Family
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR020635	Tyr_kinase_cat_dom	Domain
IPR036352	Semap_dom_sf	Homologous_superfamily
IPR039413	RON_Sema	Domain
IPR050122	RTK	Family

Pfam: PF01403, PF01437, PF01833, PF07714

Enzyme classification (BRENDA)

• EC 2.7.10.1 — receptor protein-tyrosine kinase (BRENDA: 44 organisms, 214 substrates, 574 inhibitors, 11 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0011–0.129	4
AC-DYFE-6-CHLORO-W-NHME	0.0051	1
AC-DYFGW-NHME	0.07	1
YFEW	0.232	1

Catalyzed reactions (Rhea)

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (168 total): strand 57, helix 31, sequence variant 20, disulfide bond 11, turn 9, glycosylation site 8, splice variant 8, domain 5, binding site 4, modified residue 4, chain 3, topological domain 2, sequence conflict 2, signal peptide 1, region of interest 1, active site 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures by resolution:

PDB	Title	Method	Resolution (Å)
4FWW	Crystal structure of the Sema-PSI extracellular domains of human RON receptor tyrosine …	X-RAY DIFFRACTION	1.85
8ZKD	The Crystal Structure of the RON from Biortus.	X-RAY DIFFRACTION	2.05
3PLS	RON in complex with ligand AMP-PNP	X-RAY DIFFRACTION	2.24
4QT8	Crystal Structure of RON Sema-PSI-IPT1 extracellular domains in complex with MSP …	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q04912-F1	80.23	0.46

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Transferases, Kinases, Tyr protein kinases, CD markers, Predicted membrane proteins, Predicted intracellular proteins, Disease related genes, FDA approved drug targets, Small molecule drugs, Human disease related genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol

Antibody reliability (HPA): IH enhanced · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
1208	proton acceptor

Ligand- & substrate-binding residues (4)

Position	Role
1088–1096	ATP
1114	ATP
1161–1164	ATP
1212	ATP

Post-translational modifications (4)

Type	Positions
Phosphotyrosine	1238, 1239, 1353, 1360

Disulfide bonds (11)

Type	Positions
Disulfide bond	101–104, 107–162, 135–143, 174–177, 300–367, 385–407, 386–422, 527–545, 533–567, 536–552, 548–558

Glycosylation sites (8)

Type	Positions
N-linked (glcnac…) asparagine	66, 419, 458, 488, 654, 720, 841, 897

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-8852405	Signaling by MST1	curated
R-HSA-162582	Signal Transduction	—
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	—

MSigDB gene sets: 195 (showing top): GOBP_SINGLE_FERTILIZATION, GOBP_REGULATION_OF_PHOSPHORYLATION, MODULE_255, GOBP_RESPONSE_TO_PEPTIDE, JAEGER_METASTASIS_DN, MODULE_64, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, MODULE_317, GOCC_CELL_SURFACE, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_VESICLE_MEDIATED_TRANSPORT, HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN, KANG_FLUOROURACIL_RESISTANCE_DN, MARTINEZ_RB1_TARGETS_UP, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY

GO Biological Process (16): phagocytosis (GO:0006909), defense response (GO:0006952), signal transduction (GO:0007165), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), single fertilization (GO:0007338), nervous system development (GO:0007399), positive regulation of cell population proliferation (GO:0008284), response to virus (GO:0009615), cell migration (GO:0016477), positive regulation of MAP kinase activity (GO:0043406), innate immune response (GO:0045087), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), immune system process (GO:0002376), protein phosphorylation (GO:0006468), macrophage colony-stimulating factor signaling pathway (GO:0038145), semaphorin-plexin signaling pathway (GO:0071526)

GO Molecular Function (11): transmembrane receptor protein tyrosine kinase activity (GO:0004714), macrophage colony-stimulating factor receptor activity (GO:0005011), ATP binding (GO:0005524), enzyme binding (GO:0019899), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein tyrosine kinase activity (GO:0004713), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), semaphorin receptor activity (GO:0017154)

GO Cellular Component (6): stress fiber (GO:0001725), vacuole (GO:0005773), plasma membrane (GO:0005886), cell surface (GO:0009986), signaling receptor complex (GO:0043235), membrane (GO:0016020)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Signaling by Receptor Tyrosine Kinases	1
Signal Transduction	1

GO top-level categories

58 GO namespaces:

Category	Terms
cellular anatomical structure	2
endocytosis	1
response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
enzyme-linked receptor protein signaling pathway	1
fertilization	1
system development	1
animal gross anatomical part developmental process	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
response to other organism	1
cell motility	1
MAP kinase activity	1
regulation of MAP kinase activity	1
positive regulation of MAPK cascade	1
positive regulation of protein serine/threonine kinase activity	1
immune response	1
defense response to symbiont	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
positive regulation of intracellular signal transduction	1
biological_process	1
phosphorylation	1
protein modification process	1
cytokine-mediated signaling pathway	1
cellular response to macrophage colony-stimulating factor stimulus	1
cell surface receptor signaling pathway	1
protein tyrosine kinase activity	1
transmembrane receptor protein kinase activity	1
transmembrane receptor protein tyrosine kinase activity	1
macrophage colony-stimulating factor signaling pathway	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
protein binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
protein kinase activity	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
transmembrane signaling receptor activity	1
semaphorin-plexin signaling pathway	1
actomyosin	1
contractile actin filament bundle	1
cytoplasm	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
protein-containing complex	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 5 of 33 annotations. The rest are phylogenetic / computational / electronic (IEA).

5 experimentally-supported GO terms:

GO term	NS	Evidence
positive regulation of MAP kinase activity	BP	direct assay
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	BP	direct assay
response to virus	BP	direct assay
cell surface	CC	high-throughput assay
enzyme binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 1,122 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MST1R	MST1	P26927	965
MST1R	HYAL2	Q12891	788
MST1R	HGF	P14210	764
MST1R	SRSF1	Q07955	750
MST1R	SPAM1	P38567	746
MST1R	APEH	P13798	695
MST1R	HNRNPA1	P09651	636
MST1R	HYAL1	Q12794	582
MST1R	SEMA3B	Q13214	442
MST1R	RNF123	Q5XPI4	441
MST1R	ST14	Q9Y5Y6	439
MST1R	UBA7	P41226	438
MST1R	INAVA	Q3KP66	438
MST1R	SEMA6A	Q9H2E6	437
MST1R	MKNK2	Q9HBH9	427

IntAct

Human interaction partners of MST1R in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

11 partners by confidence:

Partner	Interaction type	MIscore	Records
MST1	direct interaction	0.720	5
PLXNB1	physical association	0.520	3
PLXNB2	physical association	0.520	2
PLXNB3	physical association	0.520	2
CBL	direct interaction	0.440	1
FURIN	cleavage reaction	0.440	1
PKM	phosphorylation reaction	0.440	1
UBL4A	association	0.420	1
YWHAQ	physical association	0.370	1
YWHAZ	association	0.350	1
SHTN1	proximity	0.270	1

BioGRID (206 interactions; top human partners by supporting records): BAG6 (Affinity Capture-MS; 2 records), CBL (Affinity Capture-Western; 2 records), CDC37 (Affinity Capture-MS; 2 records), GAB1 (Affinity Capture-Western; 2 records), GRB2 (Reconstituted Complex; 2 records), HSPA1B (Affinity Capture-MS; 2 records), PPP1CA (Biochemical Activity; 2 records), STUB1 (Biochemical Activity; 2 records), UBL4A (Affinity Capture-MS; 2 records), ADCY7 (Co-fractionation), AGGF1 (Proximity Label-MS), AIMP1 (Proximity Label-MS), AKAP1 (Proximity Label-MS), AKT1 (Biochemical Activity), ALDH6A1 (Co-fractionation)

SIGNOR signaling

9 signaling interactions:

A	Effect	B	Mechanism
AKT	up-regulates	MST1R	phosphorylation
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-3-pyridinecarboxamide	down-regulates	MST1R	“chemical inhibition”
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide	down-regulates	MST1R	“chemical inhibition”
MK-2461	down-regulates	MST1R	“chemical inhibition”
AKT1	up-regulates	MST1R	phosphorylation
MST1R	“up-regulates activity”	CTNNB1	phosphorylation
EGFR	“up-regulates activity”	MST1R	phosphorylation
MST1	up-regulates	MST1R	binding
MST1R	“up-regulates activity”	ABL1	phosphorylation

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
★ MET-MST1R complex	2	MET, MST1R

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
MST1	receptor

Disease & clinical

Genetic variants

Variant evidence for MST1R: 273 ClinVar records (1 pathogenic / likely pathogenic); 19 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

273 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	195
Likely benign	27
Benign	16

Top pathogenic / likely-pathogenic (1)

Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
800321	NM_002447.4(MST1R):c.1477G>T (p.Asp493Tyr)	Likely pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore MST1R’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 28 predictions of 1,921):

Position(s)	Effect	Δscore	Sites
3:49887563–49887564	acceptor_loss	1.0000	5
3:49890484	donor_loss	1.0000
3:49890652	acceptor_gain	1.0000
3:49891397–49891398	donor_loss	1.0000	5
3:49895263	donor_gain	1.0000
3:49897417–49897418	acceptor_loss	1.0000	5
3:49898689–49898690	acceptor_loss	1.0000	3
3:49890483–49890484	donor_loss	0.9900	5
3:49890651	acceptor_gain	0.9900
3:49890658	acceptor_gain	0.9900

AlphaMissense

1,976 missense substitutions predicted likely pathogenic (of 9,011 scored), across 540 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M1196	9	0.878	0.966
M1254	9	0.857	0.960
D1269	8	0.963	0.982
H1206	8	0.953	0.989
F228	8	0.949	0.993
D1208	8	0.946	0.986
F350	8	0.940	0.984
F1128	8	0.936	0.990
D1226	8	0.932	0.978
N1213	8	0.929	0.969
F1227	8	0.927	0.985
F1093	8	0.921	0.992
D437	8	0.914	0.959
F764	8	0.894	0.981
F1334	8	0.892	0.975
F1188	8	0.868	0.973
D176	8	0.860	0.953
F511	8	0.848	0.954
F253	8	0.830	0.952
C143	7	0.975	0.991

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Lung Adenocarcinoma (validation)	unfavorable	3.86e-05
Thyroid Carcinoma (TCGA)	favorable	0.000659

Disease associations

OMIM: gene MIM:600168 | disease phenotypes: MIM:254500

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
nasopharyngeal carcinoma, susceptibility to, 3	Limited	Autosomal dominant

Mondo (2): plasma cell myeloma (MONDO:0009693), nasopharyngeal carcinoma, susceptibility to, 3 (MONDO:0014902)

Orphanet (2): Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

2 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0100630	Neoplasia of the nasopharynx

GWAS associations

19 associations:

Study	Trait	p-value
GCST001725_77	Inflammatory bowel disease	1e-47
GCST010988_346	Adult body size	2e-37
GCST008129_64	Body mass index	9e-26
GCST010698_7	Subcortical volume (min-P)	3e-24
GCST010701_11	Cortical surface area (MOSTest)	1e-16
GCST011122_18	Walking pace	6e-16
GCST003795_3	Age at first birth	5e-15
GCST010002_422	Refractive error	4e-14
GCST010703_214	Brain morphology (MOSTest)	2e-13
GCST010702_18	Subcortical volume (MOSTest)	1e-10
GCST006045_5	Age at first birth	6e-10
GCST006920_7	Regular attendance at a gym or sports club	6e-10
GCST005951_59	Body mass index	1e-8
GCST006922_9	Regular attendance at a religious group	3e-8
GCST007559_12	Sleep duration (short sleep)	3e-8
GCST007044_11	Extremely high intelligence	4e-8
GCST010699_3	Brain morphology (min-P)	4e-8
GCST002548_9	Ulcerative colitis	8e-7
GCST006044_2	Age at first birth	2e-6

EFO canonical traits (from GWAS)

5 canonical traits:

EFO ID	Trait name
EFO:0009101	age at first birth measurement
EFO:0004340	body mass index
EFO:0009592	social interaction measurement
EFO:0004337	intelligence
EFO:0004346	neuroimaging measurement

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2689 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the MST1R protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

4 curated-mechanism drugs:

Drug	Modality	Max phase
CRIZOTINIB	Small molecule	4
GLESATINIB	Small molecule	2
NARNATUMAB	Antibody	2
MK-8033	Small molecule	1

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 159,040 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

42 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL601719	CRIZOTINIB	4	15,133
CHEMBL1173655	AFATINIB	4	15,878
CHEMBL288441	BOSUTINIB	4	12,869
CHEMBL2105717	CABOZANTINIB	4	11,799
CHEMBL1983268	ENTRECTINIB	4	3,737
CHEMBL2103830	FOSTAMATINIB	4	4,026
CHEMBL3301622	GILTERITINIB	4	2,542
CHEMBL1852688	INFIGRATINIB	4	2,298
CHEMBL1834657	INFIGRATINIB PHOSPHATE	4	330
CHEMBL180022	NERATINIB	4	9,891
CHEMBL189963	PALBOCICLIB	4	13,796
CHEMBL24828	VANDETANIB	4	43,290
CHEMBL415049	BARASERTIB	3	2,469
CHEMBL491473	CEDIRANIB	3	9,464
CHEMBL522892	DOVITINIB	3	5,162
CHEMBL603469	LESTAURTINIB	3
CHEMBL223360	LINIFANIB	3	4,094
CHEMBL3989914	GLESATINIB	2	1,584
CHEMBL575448	BMS-754807	2	418
CHEMBL460702	BMS-777607	2	260
CHEMBL1967878	CENISERTIB	2
CHEMBL215152	DEFOSBARASERTIB	2
CHEMBL1230609	FORETINIB	2
CHEMBL3039525	GOLVATINIB	2
CHEMBL1980297	ILORASERTIB	2
CHEMBL3545307	MERESTINIB	2
CHEMBL564829	MILCICLIB	2
CHEMBL1822792	MK-2461	2
CHEMBL253969	OSI-632	2
CHEMBL475251	R-406	2
CHEMBL1738757	REBASTINIB	2
CHEMBL565612	SOTRASTAURIN	2
CHEMBL572878	TOZASERTIB	2
CHEMBL2323775	MK-8033	1
CHEMBL574738	AST-487	1
CHEMBL482967	CYC-116	1
CHEMBL1908397	KW-2449	1
CHEMBL49120	PD-0166285	1
CHEMBL1084546	PF-00562271	1
CHEMBL4289017	PF-03814735	1
CHEMBL1980391	RG-1530	1
CHEMBL3545085	XL-228	1

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Type X RTKs: HGF (hepatocyte growth factor) receptor family

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
BMS-777607	Inhibition	8.74	pIC50
compound 19a [PMID: 30503936]	Inhibition	8.54	pIC50
MK-2461	Inhibition	8.15	pIC50
merestinib	Inhibition	7.92	pIC50
compound 8i [PMID: 22765894]	Inhibition	6.91	pIC50

Binding affinities (BindingDB)

153 measured of 259 human assays (261 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL5430218	IC50	0.16 nM
CHEMBL5427445	IC50	0.26 nM
CHEMBL5419134	IC50	0.28 nM
1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	KD	0.37 nM
CHEMBL5396164	IC50	0.39 nM
CHEMBL5421161	IC50	0.48 nM
CHEMBL5411457	IC50	0.48 nM
CHEMBL5440908	IC50	0.49 nM
CHEMBL5398932	IC50	0.62 nM
CHEMBL5397231	IC50	0.63 nM
CHEMBL5431928	IC50	0.69 nM
CHEMBL5436390	IC50	0.72 nM
CHEMBL5424053	IC50	0.73 nM
CHEMBL5437130	IC50	0.74 nM
CHEMBL5400656	IC50	0.81 nM
CHEMBL5405709	IC50	0.82 nM
CHEMBL5411204	IC50	0.86 nM
CHEMBL5431851	IC50	0.98 nM
CHEMBL2419669	IC50	1.4 nM
CHEMBL2143592	IC50	1.7 nM
CHEMBL5429072	IC50	1.8 nM
CHEMBL5400847	IC50	2.2 nM
CHEMBL5429366	IC50	2.3 nM
CHEMBL5399763	IC50	2.3 nM
CHEMBL5395573	IC50	2.4 nM
CHEMBL5429043	IC50	2.6 nM
N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide	IC50	2.7 nM
N-(5-Amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-2-methylbenzamide	IC50	2.71 nM
CHEMBL5438831	IC50	2.8 nM
CEP-701	KD	3.4 nM
CHEMBL5395266	IC50	3.7 nM
CHEMBL4753082	IC50	3.9 nM
CHEMBL5404435	IC50	4 nM
N-[3-fluoro-4-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]phenyl]-1-phenyl-5-(trifluoromethyl)pyrazole-4-carboxamide	IC50	4.3 nM	US-9283225: Pyrido-pyrimidine derivatives
CHEMBL5409449	IC50	4.3 nM
4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	IC50	5.5 nM
CHEMBL5425777	IC50	5.5 nM
3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	IC50	5.6 nM	US-8822500: Tyrosine kinase inhibitors
CHEMBL5394757	IC50	6 nM
Staurosporine, 8	IC50	6.5 nM
Momelotinib	IC50	8 nM	US-9469613: (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
ASP-3026	IC50	10 nM
N-[3-fluoro-4-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]phenyl]-5-methyl-1-phenylpyrazole-4-carboxamide	IC50	10 nM	US-9283225: Pyrido-pyrimidine derivatives
CHEMBL3582033	IC50	10 nM
CHEMBL3608551	IC50	10 nM
CHEMBL5433417	IC50	10 nM
CHEMBL5403688	IC50	10 nM
N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide	IC50	12 nM
CHEMBL2376650	IC50	12 nM
CHEBI:72317	IC50	14 nM

ChEMBL bioactivities

354 potent at pChembl≥5 of 383 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.80	IC50	0.16	nM	CHEMBL5430218
9.60	Ki	0.2512	nM	CHEMBL1980995
9.59	IC50	0.26	nM	CHEMBL5427445
9.55	IC50	0.28	nM	CHEMBL5419134
9.41	IC50	0.39	nM	CHEMBL5396164
9.39	IC50	0.41	nM	CHEMBL5404435
9.32	IC50	0.48	nM	CHEMBL5421161
9.32	IC50	0.48	nM	CHEMBL5411457
9.31	IC50	0.49	nM	CHEMBL5440908
9.21	IC50	0.62	nM	CHEMBL5398932
9.20	IC50	0.63	nM	CHEMBL5397231
9.16	IC50	0.69	nM	CHEMBL5431928
9.14	IC50	0.73	nM	CHEMBL5424053
9.14	IC50	0.72	nM	CHEMBL5436390
9.13	IC50	0.74	nM	CHEMBL5437130
9.09	IC50	0.82	nM	CHEMBL5405709
9.09	IC50	0.81	nM	CHEMBL5400656
9.07	IC50	0.86	nM	CHEMBL5411204
9.01	IC50	0.98	nM	CHEMBL5431851
9.00	Ki	1	nM	CHEMBL2031893
8.92	IC50	1.2	nM	MERESTINIB
8.89	Ki	1.3	nM	CHEMBL447602
8.80	Ki	1.585	nM	CHEMBL1980407
8.74	IC50	1.8	nM	BMS-777607
8.74	IC50	1.8	nM	CHEMBL4753082
8.74	IC50	1.82	nM	CHEMBL5429072
8.69	IC50	2.05	nM	FORETINIB
8.69	IC50	2.04	nM	CHEMBL5395266
8.67	IC50	2.15	nM	CHEMBL5400847
8.65	IC50	2.25	nM	CHEMBL5399763
8.64	IC50	2.28	nM	CHEMBL5429366
8.62	IC50	2.39	nM	CHEMBL5409449
8.62	IC50	2.39	nM	CHEMBL5395573
8.59	IC50	2.55	nM	CHEMBL5429043
8.55	IC50	2.83	nM	CHEMBL5438831
8.54	IC50	2.9	nM	CHEMBL4587222
8.52	IC50	3	nM	FORETINIB
8.52	Kd	3	nM	FORETINIB
8.51	IC50	3.1	nM	CHEMBL4171115
8.46	IC50	3.43	nM	FORETINIB
8.46	IC50	3.48	nM	FORETINIB
8.45	IC50	3.54	nM	FORETINIB
8.44	IC50	3.62	nM	FORETINIB
8.41	IC50	3.92	nM	FORETINIB
8.40	Ki	3.981	nM	CENISERTIB
8.37	IC50	4.3	nM	CHEMBL3899652
8.26	IC50	5.47	nM	CHEMBL5425777
8.26	IC50	5.5	nM	CRIZOTINIB
8.24	IC50	5.71	nM	CHEMBL5433417
8.22	IC50	6	nM	CHEMBL5394757

PubChem BioAssay actives

219 with measured affinity, of 1602 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-methoxyazetidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0002	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(4-methylpiperazin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0003	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0003	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0004	uM
4-ethoxy-N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0004	uM
N-[4-[2-[5-[(3,3-difluoroazetidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0005	uM
N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxo-4-propoxypyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0005	uM
4-ethoxy-1-(4-fluorophenyl)-N-[3-fluoro-4-(2-pyridin-2-ylthieno[3,2-b]pyridin-7-yl)oxyphenyl]-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0005	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-fluoroazetidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0006	uM
N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-4-(2-methylpropoxy)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0006	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(4-methoxypiperidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-methoxypyrrolidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-(2-cyclopropylethoxy)-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(3-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0007	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-2-oxo-1-phenylpyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0008	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(3-fluoropyrrolidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0008	uM
N-[4-[2-[5-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0009	uM
4-butoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0010	uM
N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-1,5-dimethyl-3-oxo-2-phenylpyrazole-4-carboxamide	662101: Inhibition of RON by HTRF assay	ki	0.0010	uM
N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide	1533355: Inhibition of RON (unknown origin) by FISH assay	ic50	0.0012	uM
2-(4-fluoroanilino)-5-[5-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy-2-pyridinyl]-3-methylpyrimidin-4-one	364260: Inhibition of phosphorylated RON	ki	0.0013	uM
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-4-methoxy-2-oxopyridine-3-carboxamide	1691612: Inhibition of Ron (unknown origin)	ic50	0.0018	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-[(4-fluoropiperidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0018	uM
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	1534900: Inhibition of RON (unknown origin)	ic50	0.0018	uM
1-[(2S)-2-(2,4-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0020	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0021	uM
4-[2-(dimethylamino)ethoxy]-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0022	uM
N-[3,5-difluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0022	uM
N-[3-chloro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0023	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(2-morpholin-4-ylethoxy)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0024	uM
1-[2-(2,4-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0024	uM
1-(4-chlorophenyl)-4-ethoxy-N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0026	uM
4-ethoxy-N-[3-fluoro-4-[2-[5-(2-morpholin-4-ylethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0028	uM
1-[2-(2,6-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1533587: Inhibition of Ron (unknown origin) using FAM-labelled peptide and ATP incubated for 10 mins by mobility shift assay	ic50	0.0029	uM
N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1H-pyridine-3-carboxamide	1276923: Inhibition of Ron (unknown origin)	ic50	0.0030	uM
1-[2-(2,6-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[2-fluoro-4-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-yl]oxyphenyl]urea	1352741: Inhibition of Ron (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA	ic50	0.0031	uM
4-[[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]iminomethyl]-5-methyl-2-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-one	1800438: HTRF kinase assay from Article 10.1016/j.bioorg.2014.07.011: “Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.”	ic50	0.0042	uM
Crizotinib	2161836: Inhibition of human N-terminal GST-fused RON cytoplasmic domain (979 to 1400(end) residues) expressed in baculovirus expression system using Srctide as substrate measured after 1 hr by off-chip mobility shift assay relative to control	ic50	0.0055	uM
N-[3-fluoro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-(4-fluorophenyl)-4-(1-methylpyrrolidin-3-yl)oxy-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0055	uM
1-[(2R)-2-(2,4-difluorophenyl)-4-oxo-1,3-thiazolidin-3-yl]-3-[4-[7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-3,5-difluorophenyl]urea	1986472: Inhibition of RON (unknown origin) by kinome scan assay	ic50	0.0057	uM
N-[4-[2-[5-[(4,4-difluoropiperidin-1-yl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0060	uM
14-(dimethylsulfamoylamino)-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene	728081: Inhibition of RON (unknown origin) by TR-FRET assay	ic50	0.0070	uM
14-[[[(2R)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene	606069: Inhibition of human Ron	ic50	0.0070	uM
1-[5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-14-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide	1534900: Inhibition of RON (unknown origin)	ic50	0.0070	uM
N-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide	2015471: Inhibition of RON (unknown origin)	ic50	0.0090	uM
N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-phenyl-2-(trifluoromethyl)pyrrole-3-carboxamide	1228792: Inhibition of RON (unknown origin) transfected in 293T cells assessed as autophosporylated level by ELISA	ic50	0.0100	uM
1-(2-hydroxy-2-methylpropyl)-N-[5-(7-methoxyquinolin-4-yl)oxy-2-pyridinyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide	662101: Inhibition of RON by HTRF assay	ic50	0.0100	uM
N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-phenyl-5-(trifluoromethyl)pyrazole-4-carboxamide	1241723: Inhibition of human RON	ic50	0.0100	uM
N-[2-chloro-4-[2-[5-(morpholin-4-ylmethyl)-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide	2015473: Inhibition of N-terminal GST-tagged human recombinant RON (979 to 1400(end) residues) expressed in Sf21 cells incubated for 20 mins followed by ATP addition measured after 60 mins by TR-FRET based LanthaScreen kinase assay	ic50	0.0103	uM
N-[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-phenyl-5-(trifluoromethyl)imidazole-4-carboxamide	1228792: Inhibition of RON (unknown origin) transfected in 293T cells assessed as autophosporylated level by ELISA	ic50	0.0130	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
Particulate Matter	affects expression, decreases expression	2
methyleugenol	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases abundance, affects cotreatment, decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
pyrrolidine dithiocarbamic acid	decreases expression	1
benzo(e)pyrene	decreases methylation	1
cupric chloride	increases expression	1
nickel sulfate	decreases expression, increases expression	1
pentanal	increases expression	1
jinfukang	increases expression	1
NSC 689534	increases expression	1
5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one	decreases activity	1
Arsenic Trioxide	decreases response to substance	1
Arsenic	increases abundance, affects cotreatment, decreases expression	1
Curcumin	decreases reaction, increases expression, decreases expression, affects binding	1
Methapyrilene	decreases methylation	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Valproic Acid	decreases expression, increases methylation	1
Vanadium	decreases expression	1
Asbestos, Crocidolite	decreases expression	1
Antirheumatic Agents	decreases expression	1

ChEMBL screening assays

384 unique, capped per target: 382 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1006336	Binding	Inhibition of Tel-fused RON kinase-mediated mouse BaF3 cell proliferation	Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. — *Proc Natl Acad Sci U S A*
CHEMBL1964103	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MST1R	PubChem BioAssay data set

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C7DA	Abcam A-549 MST1R KO	Cancer cell line	Male
CVCL_C7E0	Abcam HCT 116 MST1R KO	Cancer cell line	Male
CVCL_D3UF	MDCK-RE7	Spontaneously immortalized cell line	Female
CVCL_D7VC	Ubigene A-549 MST1R KO	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00029224	Phase 4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104	Phase 4	COMPLETED	A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211	Phase 4	COMPLETED	FREE Study - Fracture Reduction Evaluation
NCT00242528	Phase 4	WITHDRAWN	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114	Phase 4	COMPLETED	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703	Phase 4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140	Phase 4	COMPLETED	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505	Phase 4	COMPLETED	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041	Phase 4	COMPLETED	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538	Phase 4	COMPLETED	Stage I Multiple Myeloma Treatment
NCT01087008	Phase 4	COMPLETED	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690	Phase 4	UNKNOWN	Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929	Phase 4	WITHDRAWN	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886	Phase 4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828	Phase 4	UNKNOWN	A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890	Phase 4	COMPLETED	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830	Phase 4	COMPLETED	Prolonged Protection From Bone Disease in Multiple Myeloma
NCT02559154	Phase 4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783	Phase 4	UNKNOWN	PDD vs PAD to Treat Initially Diagnosed MM
NCT02773550	Phase 4	TERMINATED	Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969	Phase 4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092	Phase 4	TERMINATED	A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252	Phase 4	COMPLETED	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960	Phase 4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371	Phase 4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138	Phase 4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967	Phase 4	COMPLETED	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766	Phase 4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140	Phase 4	UNKNOWN	Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139	Phase 4	WITHDRAWN	A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781	Phase 4	RECRUITING	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515	Phase 4	NOT_YET_RECRUITING	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428	Phase 4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202	Phase 4	UNKNOWN	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329	Phase 4	COMPLETED	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405	Phase 4	RECRUITING	Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122	Phase 4	UNKNOWN	Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783	Phase 4	NOT_YET_RECRUITING	Bioequivalence Studies of Dasatinib 100 Mg
NCT06057402	Phase 4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076	Phase 4	RECRUITING	Plan Development for Giving Teclistamab in the Outpatient Setting
NCT06409702	Phase 4	RECRUITING	Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT06425276	Phase 4	COMPLETED	Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
NCT07030517	Phase 4	ACTIVE_NOT_RECRUITING	A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07094048	Phase 4	RECRUITING	Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
NCT07101445	Phase 4	RECRUITING	Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
NCT07154537	Phase 4	ACTIVE_NOT_RECRUITING	Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
NCT07334535	Phase 4	NOT_YET_RECRUITING	Isa-VRD in TIE HRMM
NCT07474961	Phase 4	NOT_YET_RECRUITING	BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
NCT00001561	Phase 3	COMPLETED	Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
NCT00002548	Phase 3	COMPLETED	SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
NCT00002556	Phase 3	COMPLETED	Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
NCT00002850	Phase 3	COMPLETED	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
NCT00005834	Phase 3	TERMINATED	S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
NCT00037791	Phase 3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00038233	Phase 3	COMPLETED	Thalidomide for Multiple Myeloma
NCT00048230	Phase 3	COMPLETED	PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00056160	Phase 3	COMPLETED	CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00057564	Phase 3	COMPLETED	A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
NCT00063726	Phase 3	COMPLETED	A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
NCT00064038	Phase 3	COMPLETED	S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for MST1R across ~30M SureChEMBL compounds — explore on Sugi Predict.